3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Completed
2
Sponsor Class
INDUSTRY
30
OTHER
25
NETWORK
2
Study Type
Interventional
2
Sponsor
Cancer Type
Plasma cell
2
Conditions
Multiple Myeloma
1
Immunoglobulin Light-chain Amyloidosis
1
Interventions
Radiotherapy
299
Cisplatin
263
Cyclophosphamide
229
Doxorubicin
176
Paclitaxel
166
Vincristine
160
Carboplatin
149
Filgrastim
139
Etoposide
139
Gemcitabine
118
Fluorouracil
113
Docetaxel
112
Methotrexate
106
Dexamethasone
106
Cytarabine
106
Prednisone
91
Leucovorin
90
Granulocyte Colony-Stimulating Factor
74
Specimen Handling
65
Magnetic Resonance Spectroscopy
61
Capecitabine
59
Irinotecan
58
Radiation
54
Ifosfamide
51
Oxaliplatin
48
Daunorubicin
48
Temozolomide
47
Radiotherapy, Conformal
47
Platinum
47
Peripheral Blood Stem Cell Transplantation
47
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
NETWORK
×
Interventional
×
belantamab mafodotin
×
Clear all
NCT04617925
2025-09-05
EMN27
European Myeloma Network B.V.
Phase 2
Completed
35 enrolled
NCT03732703
2025-02-14
MyDRUG
Multiple Myeloma Research Consortium
Phase 1/2
Completed
103 enrolled